In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo
- PMID: 37399554
- DOI: 10.7326/J23-0044
In statin-intolerant adults with, or at risk for, CV disease, bempedoic acid reduced MACE at a median 41 mo
Abstract
Nissen SE, Lincoff MA, Brennan D, et al; CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353-1364. 36876740.
Conflict of interest statement
Comment on
-
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical